Page 85 - An Evidence Review of Active Surveillance in Men With Localized Prostate Cancer

Table 5. Monitoring criteria in protocols with curative intent in chronological order of starting enrollment year (continued)
Center, Country Monitoring Gleason # biopsy cores PSA Imaging Behavioral Additional laboratory Triggers for
[Pubmed ID] schedule score /% cores indication tests interventions
Enrollment years
Royal Marsden Every 3-6 mo >7 124 TRUS-guided PSA DT<4 yr 124 Repeat – – Rate of rise of
Hospital, PSA and DRE octant biopsy at imaging only PSA, according
UK 112,124,128 for 2 yr and Primary 18-24 mo. PSA velocity >1 if clinically to judgment of
[15839912; every 6 mo Gleason ≥4, Sextant or ng/mL/yr based indicated. 112 each patient and
17850368; thereafter. (initial Gleason octant on a minimum of clinician. 112
18949747] Rebiopsy not 3+3, upgraded ≥50% biopsy 4 values
routine. 112 to Gleason cores observed over PSA DT<4 yr,
1993-2002; ≥3+4) 134,136 positive. 124 minimum of 6 histologic
≥2002; 124 2004- After 2002; mo 128,134 progression, or
2006 134 monthly PSA in patient
yr 1, every 3 mo preference, or
in yr 2, and PSA velocity >1
every 6 mo ng/mL/yr 128
thereafter. 124,134
DRE every 3 mo
for 2 yr.
Johns Hopkins, Every 6 mo PSA ≥7; or >2 cores cancer √ (PSA kinetics – Patient – Annual
US 113 and DRE; Gleason positive; or not used as a request for surveillance
[20439642] annual extended pattern 4 or 5 single core trigger for curative biopsy: Gleason
12-core biopsy >50% cancer intervention) treatment 137 ≥7; or Gleason
1994-2008 (from annual pattern 4 or 5; or
extended 12- >2 cores cancer
core biopsy) positive; or
single core
>50% cancer.

43